1. Suppressed expression of Cbl‐b by NF‐κB mediates icotinib resistance in EGFR‐mutant non‐small‐cell lung cancer
   Tieqiong Zhang et al, 2019, Cell Biology International CrossRef
2. Kinase-Inactivated EGFR Is Required for the Survival of Wild-Type EGFR-Expressing Cancer Cells Treated with Tyrosine Kinase Inhibitors
   Rintu Thomas et al, 2019, International Journal of Molecular Sciences CrossRef
3. Rose (Rosa gallica) Petal Extract Suppress Proliferation, Migration, and Invasion of Human Lung Adenocarcinoma A549 Cells through via the EGFR Signaling Pathway
   Won-Chul Lim et al, 2020, Molecules CrossRef
4. Hype or hope – Can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant advanced/metastatic NSCLC?
   Filippo Papini et al, 2021, Critical Reviews in Oncology/Hematology CrossRef
5. Concurrent ROS1 gene rearrangement and KRAS mutation in lung adenocarcinoma: A case report and literature review
   You‐cai Zhu et al, 2018, Thoracic Cancer CrossRef
6. Dual targeting of MEK and PI3K effectively controls the proliferation of human EGFR-TKI resistant non-small cell lung carcinoma cell lines with different genetic backgrounds
   Ge-Ping Qu et al, 2021, BMC Pulmonary Medicine CrossRef
7. Costunolide is a dual inhibitor of MEK1 and AKT1/2 that overcomes osimertinib resistance in lung cancer
   Xueli Tian et al, 2022, Molecular Cancer CrossRef
8. The cell line models to study tyrosine kinase inhibitors in non-small cell lung cancer with mutations in the epidermal growth factor receptor: A scoping review
   Alessia Belloni et al, 2024, Critical Reviews in Oncology/Hematology CrossRef
9. Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells
   Zhongwei Liu et al, 2017, Toxicology and Applied Pharmacology CrossRef
10. DRSPRING: Graph convolutional network (GCN)-Based drug synergy prediction utilizing drug-induced gene expression profile
    Jiyeon Han et al, 2024, Computers in Biology and Medicine CrossRef
11. Chinese herbal medicine Fuzheng Kang-Ai decoction sensitized the effect of gefitinib on inhibition of human lung cancer cells through inactivating PI3-K/Akt -mediated suppressing MUC1 expression
    Longmei Li et al, 2016, Journal of Ethnopharmacology CrossRef
12. MEK inhibitors for the treatment of non-small cell lung cancer
    Jing Han et al, 2021, Journal of Hematology & Oncology CrossRef
13. Drug combination approach to overcome resistance to EGFR tyrosine kinase inhibitors in lung cancer
    Christy W.S. Tong et al, 2017, Cancer Letters CrossRef
14. Current Strategies for Treating NSCLC: From Biological Mechanisms to Clinical Treatment
    Junnan Li et al, 2020, Cancers CrossRef
15. Ibrutinib in the Treatment of Solid Tumors: Current State of Knowledge and Future Directions
    Katarzyna Szklener et al, 2022, Cells CrossRef